Cellular Biomedicine Group, Inc., a clinical stage biopharmaceutical company, develops therapies for cancer and degenerative diseases in Greater China. It focuses on developing and marketing cell-based therapies to treat various diseases, such as cancer, orthopedic, and metabolic diseases. The company develops treatments utilizing proprietary cell based technologies, including immune cell therapy for the treatment of a range of cancers; human adipose-derived mesenchymal progenitor cells for the treatment of joint and autoimmune diseases; tumor cell specific dendritic cell therapy; and Re-Join therapy and AlloJoin therapy for the treatment of knee osteoarthritis. It also engages in the research and production of lab kits. The company has a strategic research collaboration with GE Healthcare Life Science to co-develop industrial control processes in chimeric antigen receptor T-cell and stem cell manufacturing; and Novartis to manufacture and supply the CAR-T cell therapy KymriahÂ. Cellular Biomedicine Group, Inc. was incorporated in 2001 and is headquartered in Cupertino, California.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:CBMG
Previous Symbol
CUSIPN/A
Phone408-973-7884
Debt
Debt-to-Equity RatioN/A
Current Ratio11.86
Quick Ratio11.86
Price-To-Earnings
Trailing P/E Ratio-11.29
Forward P/E Ratio-11.55
P/E GrowthN/A
Sales & Book Value
Annual Sales$340,000.00
Price / Sales1,087.76
Cash FlowN/A
Price / Cash FlowN/A
Book Value$3.77 per share
Price / Book5.33
Profitability
EPS (Most Recent Fiscal Year)($1.78)
Net Income$-25,490,000.00
Net Margins-13,988.39%
Return on Equity-44.62%
Return on Assets-41.84%
Miscellaneous
Employees125
Outstanding Shares18,400,000
Market Cap$373.08 million
OptionableOptionable
Cellular Biomedicine Group (NASDAQ:CBMG) Frequently Asked Questions
What is Cellular Biomedicine Group's stock symbol?
Cellular Biomedicine Group trades on the NASDAQ under the ticker symbol "CBMG."
How will Cellular Biomedicine Group's stock buyback program work?
Cellular Biomedicine Group declared that its board has initiated a stock buyback plan on Sunday, June 4th 2017, which allows the company to buyback $10,000,000.00 in outstanding shares, according to EventVestor. This buyback authorization allows the company to repurchase shares of its stock through open market purchases. Shares buyback plans are usually a sign that the company's board believes its shares are undervalued.
How were Cellular Biomedicine Group's earnings last quarter?
Cellular Biomedicine Group Inc (NASDAQ:CBMG) issued its earnings results on Tuesday, November, 6th. The biotechnology company reported ($0.56) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.52) by $0.04. The biotechnology company earned $0.07 million during the quarter, compared to analyst estimates of $0.05 million. Cellular Biomedicine Group had a negative net margin of 13,988.39% and a negative return on equity of 44.62%. View Cellular Biomedicine Group's Earnings History.
When is Cellular Biomedicine Group's next earnings date?
What price target have analysts set for CBMG?
2 equities research analysts have issued 12 month target prices for Cellular Biomedicine Group's stock. Their predictions range from $38.00 to $38.00. On average, they expect Cellular Biomedicine Group's stock price to reach $38.00 in the next twelve months. This suggests a possible upside of 89.1% from the stock's current price. View Analyst Price Targets for Cellular Biomedicine Group.
What is the consensus analysts' recommendation for Cellular Biomedicine Group?
2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cellular Biomedicine Group in the last year. There are currently 1 hold rating and 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Cellular Biomedicine Group.
Has Cellular Biomedicine Group been receiving favorable news coverage?
News articles about CBMG stock have trended neutral this week, InfoTrie Sentiment reports. InfoTrie identifies negative and positive press coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Cellular Biomedicine Group earned a media sentiment score of 0.3 on InfoTrie's scale. They also gave news articles about the biotechnology company a news buzz of 2.0 out of 10, indicating that recent press coverage is very unlikely to have an impact on the stock's share price in the next several days.
Who are some of Cellular Biomedicine Group's key competitors?
Some companies that are related to Cellular Biomedicine Group include Rubius Therapeutics (RUBY), Editas Medicine (EDIT), Autolus Therapeutics (AUTL), Orchard Therapeutics (ORTX), Iovance Biotherapeutics (IOVA), Sangamo Therapeutics (SGMO), Fate Therapeutics (FATE), Audentes Therapeutics (BOLD), BioCryst Pharmaceuticals (BCRX), Momenta Pharmaceuticals (MNTA), Novavax (NVAX), Solid Biosciences (SLDB), Cellectis (CLLS), DBV TECHNOLOGIE/S (DBVT) and Acorda Therapeutics (ACOR).
Who are Cellular Biomedicine Group's key executives?
Cellular Biomedicine Group's management team includes the folowing people:
- Mr. Bizuo Liu, CEO, CFO & Director (Age 53)
- Dr. Yihong Yao, Chief Scientific Officer (Age 50)
- Mr. Andrew K. Chan, Sr. VP of Corp. Bus. Devel., Sec. & Chief Legal Officer (Age 60)
- Dr. Xia Meng Ph.D., BS, Gen. Mang. of Early Diagnosis & Intervention
- Ms. Sarah Kelly, Director of Corp. Communications
Who are Cellular Biomedicine Group's major shareholders?
Cellular Biomedicine Group's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (3.42%), Vanguard Group Inc. (1.00%), Wells Fargo & Company MN (0.10%), TIAA CREF Investment Management LLC (0.08%) and Citadel Advisors LLC (0.06%). Company insiders that own Cellular Biomedicine Group stock include Andrew K Chan, Tony Liu, Wen Tao Liu and Yihong Yao. View Institutional Ownership Trends for Cellular Biomedicine Group.
Which institutional investors are selling Cellular Biomedicine Group stock?
Which institutional investors are buying Cellular Biomedicine Group stock?
CBMG stock was acquired by a variety of institutional investors in the last quarter, including BlackRock Inc., Citadel Advisors LLC, Vanguard Group Inc. and Wells Fargo & Company MN. Company insiders that have bought Cellular Biomedicine Group stock in the last two years include Andrew K Chan, Tony Liu and Yihong Yao. View Insider Buying and Selling for Cellular Biomedicine Group.
How do I buy shares of Cellular Biomedicine Group?
Shares of CBMG can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Cellular Biomedicine Group's stock price today?
One share of CBMG stock can currently be purchased for approximately $20.10.
How big of a company is Cellular Biomedicine Group?
Cellular Biomedicine Group has a market capitalization of $373.08 million and generates $340,000.00 in revenue each year. The biotechnology company earns $-25,490,000.00 in net income (profit) each year or ($1.78) on an earnings per share basis. Cellular Biomedicine Group employs 125 workers across the globe.
What is Cellular Biomedicine Group's official website?
How can I contact Cellular Biomedicine Group?
Cellular Biomedicine Group's mailing address is 19925 STEVENS CREEK BLVD. SUITE 100, CUPERTINO CA, 95014. The biotechnology company can be reached via phone at 408-973-7884 or via email at [email protected]
MarketBeat Community Rating for Cellular Biomedicine Group (NASDAQ CBMG)
MarketBeat's community ratings are surveys of what our community members think about Cellular Biomedicine Group and other stocks. Vote "Outperform" if you believe CBMG will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CBMG will underperform the S&P 500 over the long term. You may vote once every thirty days.
